• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Quanterix Corporation

    6/2/25 4:50:04 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email
    SD 1 a2025formsd.htm SD Document


     UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________
     
    FORM SD

    SPECIALIZED DISCLOSURE REPORT
      
    Quanterix Corporation
    (Exact name of registrant as specified in its charter)

    Delaware
    001-38319
    (State or other jurisdiction of incorporation)(Commission file number)
    900 Middlesex Turnpike, Billerica, MA 01821
    (Address of principal executive offices, zip code)

    Vandana Sriram
    Chief Financial Officer
    (617) 301-9400
    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

    ☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2024 to December 31, 2024.

    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended .








    Section 1    Conflicts Mineral Disclosure
    Item 1.01    Conflict Minerals Disclosure and Report
    This Form SD is filed by Quanterix Corporation (“Quanterix” or, the “Company”) to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as modified by SEC guidance issued on April 29, 2014 and the SEC order issued on May 2, 2014 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement reporting and disclosure requirements related to Conflict Minerals as directed by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank Act”). The Rule imposes certain reporting obligations on SEC registrants whose manufactured products contain Conflict Minerals which are necessary to the functionality or production of their products. Conflict Minerals are defined as cassiterite, columbite-tantalite, gold, wolframite, and their derivatives, which are limited to tin, tantalum, tungsten, and gold for the purposes of this assessment. These requirements apply to registrants whether or not the Conflict Minerals in their supply chain originated in the Democratic Republic of the Congo or an adjoining country (the “Covered Countries”) and whether or not they fund armed conflict.
    Company Overview
    Quanterix is a life sciences company that develops and commercializes next-generation, ultra-sensitive digital immunoassay platforms that advance life sciences research and diagnostics. Quanterix’s platforms are based on its proprietary digital “Simoa” detection technology and enable customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. The ability of the Simoa platforms to detect proteins in the femtomolar range enables the development of novel therapies and diagnostics and has the potential to identify early-stage disease markers before symptoms appear to facilitate a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention. Simoa platforms have achieved significant commercial adoption with an installed base of over 1,000 instruments, and scientific validation with citations in more than 3,400 scientific publications in areas of high unmet medical need and research interest such as neurology, oncology and immunology, and inflammation..
    Products Overview
    The Company has three categories of products: (1) reagents and consumables; (2) instruments; and (3) spare parts for instruments. Based upon the Company’s internal assessment, the reagents and consumables have been determined not to contain any Conflict Minerals as they contain only plastics, water, salts, dyes, nucleic acids and other non-Conflict Mineral components.  
    The Company currently sells three instruments as part of its Simoa platform: (i) the HD-X Analyzer, (ii) the SP-X Imaging and Analysis System and (iii) the SR-X Biomarker Detection System. These instruments have the potential to contain Conflict Minerals necessary to their functionality or production as they contain printed circuit assemblies and other electromechanical components that are generally known to contain small amounts of tin, tungsten, tantalum or gold. Spare parts are purchased and used for the maintenance and repair of instruments previously sold to the Company’s customers and also have the potential to contain Conflict Minerals.
    Reasonable Country of Origin Inquiry
    We do not directly source any Conflict Minerals from mines, smelters or refiners. Accordingly, our reasonable country of origin inquiry (“RCOI”) was initiated by sending surveys to our direct suppliers of materials for our products that we determined were likely to contain Conflict Minerals. The suppliers surveyed were asked to complete and return the Responsible Minerals Initiative’s (“RMI”) Conflict Minerals Reporting Template (“CMRT”) version 6.4. Communications sent to the suppliers included the CMRT, as well as access to educational material on conflict minerals and assistance on how to complete the reporting template. We reviewed the responses that we received from our suppliers and followed up by email and/or telephone with those suppliers who did not respond to our requests for information. Overall, we received completed CMRTs from 25 of the 28 suppliers we contacted, a 89% response rate.




    Based on the results of our RCOI, we determined that certain suppliers may have sourced components or materials that contained necessary Conflict Minerals originating from a Covered Country. We exercised further due diligence and identified approximately 343 smelters and refiners that appear on the RMI Smelter Reference List from which our suppliers may have sourced Conflict Minerals from Covered Countries. While a majority of those smelters and refiners have completed an assessment against the applicable RMI Responsible Minerals Assurance Process (“RMAP”) standard or an equivalent cross-recognized standard, a number of the identified smelters and refiners were not conformant with the RMAP standard or an equivalent cross-recognized standard.
    Our due diligence process is based on requesting information from our direct suppliers, with those suppliers requesting similar information from their suppliers and so on, up the supply chain, in an effort intended eventually to identify the original sources of the necessary Conflict Minerals. However, those who purchase Conflict Minerals directly from smelters or refiners may not be able to discern which of its product lines include specific Conflict Minerals from each smelter or refiner, and so it is common practice for such purchasers to list all smelters and refiners they may purchase from within the reporting period. Consequently, we cannot be certain that the identified smelters and refiners supplied Conflict Minerals for parts and components supplied to us rather than to other customers. In addition, our suppliers’ CMRTs primarily provided information at the company level and not at the product level. More generally, the amount of reliable information available globally on the traceability and sourcing of Conflict Minerals is limited, which presents another challenge to our ability to precisely track any Conflict Minerals back to their source and origin. Given the foregoing limitations, we were unable to identify the specific smelters or refiners from which any Conflict Minerals in our products were extracted or refined or the mines from which the Conflict Minerals originated. Further, we cannot confirm if all such smelters or refiners are conformant with the RMAP standard or an equivalent cross-recognized standard.
    Based on the foregoing, and in light of the limitations explained above, Quanterix cannot at this time draw any definitive conclusions about the countries of origin for, or the RMAP conformant status of, the identified smelters and refiners that may be necessary to its products’ functionality or production.
    In accordance with the Rule, we have filed disclosures under paragraphs (a) and (b) of Item 1.01 of Form SD. In addition, the disclosure contained in this Form SD is available in the “Investors – Financial Information - SEC Filings” section of the Company’s website at http://www.quanterix.com. The reference to the Company’s website is provided for convenience only, and its contents are not incorporated by reference into this Form SD nor deemed filed with the SEC.


    Item 1.02    Exhibit
    Not applicable.

    Section 2    Resource Extraction Issuer Disclosure
    Item 2.01    Resource Extraction Issuer Disclosure and Report
    Not applicable.

    Section 3    Exhibits
    Item 3.01    Exhibits
    Not applicable.




    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    Quanterix Corporation
    By:/s/ Vandana Sriram
    Name:Vandana Sriram
    Title:Chief Financial Officer
    Date:June 2, 2025





    Get the next $QTRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    3/2/2022$85.00 → $60.00Overweight
    JP Morgan
    More analyst ratings

    $QTRX
    SEC Filings

    See more
    • SEC Form POS AM filed by Quanterix Corporation

      POS AM - Quanterix Corp (0001503274) (Filer)

      6/3/25 9:24:17 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Quanterix Corporation

      SD - Quanterix Corp (0001503274) (Filer)

      6/2/25 4:50:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form POS AM filed by Quanterix Corporation

      POS AM - Quanterix Corp (0001503274) (Filer)

      5/20/25 9:19:26 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      11/13/24 12:41:46 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Quanterix Corporation

      SC 13G - Quanterix Corp (0001503274) (Subject)

      6/27/24 2:46:59 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      2/14/24 4:57:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

      RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

      5/23/25 2:21:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Financials

    Live finance-specific insights

    See more
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the Fourth Quarter of 2024

      Delivers seventh consecutive quarter of double-digit revenue growth Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. "During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment," said Masoud Toloue, Chief Executive Officer of Quanterix. "Our ability to grow in a difficult environment is the result of investments in our business model, which focuses on key vertical markets and recurring revenues. We are expanding our approach to immunology and

      3/17/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Quanterix with a new price target

      Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

      2/1/24 6:32:54 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

      9/25/23 9:03:48 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by SVB Securities with a new price target

      SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00

      8/8/23 6:29:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

      Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. ("EMISSION"). Quanterix expects the transaction will close in January 2025. "As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components," said Masoud Toloue, Chief Executive Officer of Quanterix. "EMISSION's proprietary bead technology has already been validated on our upcoming new Simoa platform and will en

      12/17/24 6:59:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis

      10/2/24 4:00:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $624,630 worth of shares (47,000 units at $13.29) and gifted 2,000 shares, increasing direct ownership by 3% to 1,487,342 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      9/17/24 4:35:10 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $207,100 worth of shares (19,000 units at $10.90), increasing direct ownership by 6% to 354,119 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      8/15/24 4:03:35 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Toloue Masoud covered exercise/tax liability with 254 shares, decreasing direct ownership by 0.05% to 473,022 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/3/25 4:19:47 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Sriram Vandana covered exercise/tax liability with 229 shares, decreasing direct ownership by 0.27% to 83,737 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      5/19/25 9:15:12 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud covered exercise/tax liability with 1,242 shares, decreasing direct ownership by 0.26% to 473,276 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      5/19/25 9:14:18 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials